

Supplementary figures

Colorectal cancer bioengineered microtissues as model to replicate tumor-ECM cross-talk and assess drug delivery systems in vitro

Alessia La Rocca ^{1,2}, Vincenza De Gregorio ^{3,4}, Giorgia Imperato ^{1,3,5,*}, Elena Lagreca ^{1,5}, Raffaele Vecchione ¹, Paolo Antonio Netti ^{1,3,5}

¹ Center for Advanced Biomaterials for Health Care (CABHC), Istituto Italiano di Tecnologia, 80125 Napoli, Italy

² San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

³ Interdisciplinary Research Centre on Biomaterials (CRIB), University of Naples Federico II, 80125 Naples, Italy

⁴ Department of Biology, University of Naples Federico II, Complesso Universitario Monte S. Angelo, 80126 Naples, Italy

⁵ Department of Chemical Materials and Industrial Production (DICMaPI), University of Naples Federico II, 80125 Naples, Italy

* Correspondence: giorgia.imparato@iit.it (G.I.);




Figure S1. High magnification of different organization and structure of auto-produced ECM in 3D CRC Day4 μ Ts and 3D Stroma μ Ts; scale bar 40 μ m.




Figure S2. Absence of selective cytotoxic effect of 5-FU between less invasive colon cancer cells (Caco2) and more invasive cancer cells (HCT-116) in 2D *in vitro* cell cultures. Caco2 and HCT-116 were treated with different 5-FU concentrations and MTT analyses were carried out after 24 h, 48 h and 72 h of treatments. All the experiments were performed in triplicate (n = 3), values represent the mean and mean-standard error.




Figure S3. Synergistic effects of CT-NE-Curc and 5-FU 10 μ M and 100 μ M in 2D *in vitro* colon cancer cell cultures. Caco2 and HCT-116 cells were pre-treated with CT-NE-Curc for 2 h and then treated with 5-FU 10 μ M and 100 μ M. MTT analyses were carried out after 24 h, 48 h and 72 h of treatments. All the experiments were performed in triplicate (n = 3), values represent the mean and mean-standard error.






Figure S4: A schematic diagram of the sequence of steps for 3D μ Ts fabrication. (A) 3D CRC Day0 μ Ts production; (B) 3D Stroma μ Ts and 3D CRC Day 4 w or w/o μ Ts production; (C) 3D HCT-116 μ Ts production. Normal fibroblasts (NFs); Gelatin porous microbeads (GPMs); Ascorbic Acid (AA); 3D CRC Day4 μ Ts with Ascorbic Acid (w A) and 3D CRC Day4 without Ascorbic acid (w/o AA); Green Fluorescent Protein (GFP); Second Harmonic Generation (SHG).